文献速递泌尿生殖与妇科肿瘤放疗

宫颈鳞癌与腺癌根治性放疗或同步放化疗后治疗结局比较

Comparison of treatment outcomes between squamous cell carcinoma and adenocarcinoma of cervix after definitive radiotherapy or concurrent chemoradiotherapy.
PubMed 文献 · Radiat Oncol · 2018-12-17

本研究回顾性分析了2011年1月至2014年12月在本院接受根治性放疗或同步放化疗的815例IB-IVA期宫颈癌患者,其中鳞癌744例、腺癌71例,中位随访36.2个月。结果显示腺癌组3年总生存率、无病生存率、盆腔控制率和远处控制率均低于鳞癌组,多因素分析显示组织学类型是独立影响因素,倾向评分匹配后腺癌组仍较差。作者结论认为宫颈腺癌患者总生存和无病生存均差于鳞癌,应考虑新的治疗方法。

要点

  • 腺癌组3年总生存率75.4%低于鳞癌组85.2%(p=0.005)。
  • 腺癌组3年无病生存率57.3%低于鳞癌组77.5%(p<0.001)。
  • 匹配后腺癌总生存(p=0.017)和无病生存(p=0.001)仍差于鳞癌。

核心结论

  • 宫颈腺癌患者的总生存和无病生存均差于鳞癌患者,无论接受单纯放疗还是同步放化疗。
  • 作者认为应考虑针对宫颈腺癌的新治疗方法。

研究设计与样本

  • 回顾性分析本院2011年1月至2014年12月接受根治性放疗或同步放化疗的宫颈癌患者病历。
  • 共纳入815例IB-IVA期宫颈癌患者,鳞癌组744例,腺癌组71例。
  • 放疗采用调强放疗联合腔内近距离放疗,同步化疗一线方案为每周顺铂。
  • 采用多因素Cox回归模型和倾向评分匹配(1:1)前后对数秩检验比较鳞癌与腺癌的治疗结局。

主要发现

  • 中位随访36.2个月(范围1.0-76.2个月)。
  • 鳞癌组与腺癌组3年总生存率分别为85.2%和75.4%(p=0.005)。
  • 鳞癌组与腺癌组3年无病生存率分别为77.5%和57.3%(p<0.001)。
  • 鳞癌组与腺癌组3年盆腔控制率分别为89.0%和74.0%(p=0.001),远处控制率分别为86.0%和74.4%(p=0.011)。
  • 多因素分析显示组织学是总生存(p=0.003)、无病生存(p<0.001)、盆腔控制(p=0.002)和远处控制(p=0.003)的独立影响因素。

临床怎么用

  • 作者认为宫颈腺癌患者的总生存和无病生存差于鳞癌,应考虑新的治疗方法。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Concurrent chemoradiotherapy (CCRT) is effective in the treatment of locally advanced cervical squamous cell carcinoma (SCC). However, whether treatment outcomes of cervical adenocarcinoma are equivalent to SCC after CCRT has been a topic of debate. METHODS: Medical records of cervical cancer patients treated with definitive radiotherapy or CCRT in our institute from January 2011 to December 2014 were reviewed. Patients were treated with intensity modulated radiation therapy combined with intracavitary brachytherapy. Weekly cisplatin was the first line regimen of concurrent chemotherapy. The treatment outcomes of patients with SCC and adenocarcinoma were compared with a multivariate Cox regression model, and log-rank method before and after propensity score matching (1:1). RESULTS: A total of 815 patients with stage IB-IVA cervical cancer were included, with 744 patients in the SCC group and 71 patients in adenocarcinoma group. The median follow-up period was 36.2 months (range, 1.0-76.2 months). The 3-year overall survival (OS), disease-free survival (DFS), pelvic control and distant control rates of patients in the SCC group and adenocarcinoma group were 85.2 and 75.4% (p = 0.005), 77.5 and 57.3% (p < 0.001), 89.0 and 74.0% (p = 0.001) and 86.0 and 74.4% (p = 0.011), respectively. After multivariate analysis, histology was an independent factor of OS (p = 0.003), DFS (p < 0.001), pelvic control (p = 0.002) and distant control (p = 0.003). With propensity score matching, 71 pairs of patients were selected. After matching, the OS (p = 0.017), DFS (p = 0.001), pelvic control (p = 0.015) and distant control (p = 0.009) of patients with adenocarcinoma were poorer than those of patients with SCC. In subgroup analysis, patients with adenocarcinoma had significantly worse OS and DFS compared with patients with SCC, regardless of treatment with radiotherapy alone or CCRT. CONCLUSION: The present study demonstrated that patients with adenocarcinoma of the cervix had poorer OS and DFS than patients with SCC, regardless of treatment with radiotherapy alone or CCRT. New treatment approaches should be considered for cervical adenocarcinoma.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Hu K, Wang W, Liu X, et al. Comparison of treatment outcomes between squamous cell carcinoma and adenocarcinoma of cervix after definitive radiotherapy or concurrent chemoradiotherapy. Radiat Oncol. 2018. PMID: 30558636. doi:10.1186/s13014-018-1197-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。